|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.02 EUR | -5.23% |
|
-.--% | - |
| 06-25 | UPM-Kymmene, Andritz Enter Partnership to Develop Tissue Products | MT |
| 06-25 | UPM and Andritz to speed the development of new tissue products | FW |
Company Valuation: Andritz
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,504 | 5,312 | 5,578 | 4,859 | 6,512 | 7,526 | - | - |
| Change | - | 17.93% | 5.02% | -12.89% | 34.01% | 15.58% | - | - |
| Enterprise Value (EV) 1 | 4,114 | 4,569 | 5,128 | 4,433 | 6,011 | 6,816 | 6,633 | 6,455 |
| Change | - | 11.05% | 12.23% | -13.55% | 35.6% | 13.39% | -2.68% | -2.69% |
| P/E | 13.8x | 12.9x | 11x | 9.82x | 14.4x | 15.6x | 13.6x | 12.1x |
| PBR | 2.86x | 2.87x | 2.57x | 2.13x | 2.66x | 2.82x | 2.55x | 2.31x |
| PEG | - | 0.5x | 0.5x | -3.16x | -2.11x | 2.53x | 0.9x | 1x |
| Capitalization / Revenue | 0.7x | 0.7x | 0.64x | 0.58x | 0.83x | 0.92x | 0.86x | 0.8x |
| EV / Revenue | 0.64x | 0.61x | 0.59x | 0.53x | 0.76x | 0.83x | 0.75x | 0.69x |
| EV / EBITDA | 5.73x | 5.53x | 5.63x | 4.99x | 7.3x | 7.56x | 6.68x | 5.95x |
| EV / EBIT | 8.58x | 7.98x | 7.48x | 6.7x | 10.3x | 10.5x | 8.96x | 7.93x |
| EV / FCF | 9.81x | 8.68x | 34.5x | 11.1x | 15.7x | 10.2x | 12.1x | 10.9x |
| FCF Yield | 10.2% | 11.5% | 2.9% | 9% | 6.37% | 9.79% | 8.26% | 9.14% |
| Dividend per Share 2 | 1.65 | 2.1 | 2.5 | 2.6 | 2.7 | 2.825 | 3.05 | 3.34 |
| Rate of return | 3.64% | 3.92% | 4.43% | 5.31% | 4.04% | 3.68% | 3.97% | 4.35% |
| EPS 2 | 3.28 | 4.14 | 5.15 | 4.99 | 4.65 | 4.936 | 5.667 | 6.323 |
| Distribution rate | 50.3% | 50.7% | 48.5% | 52.1% | 58.1% | 57.2% | 53.8% | 52.8% |
| Net sales 1 | 6,463 | 7,543 | 8,660 | 8,314 | 7,883 | 8,198 | 8,791 | 9,398 |
| EBITDA 1 | 718.3 | 825.5 | 910.2 | 887.9 | 823.4 | 901 | 993.3 | 1,084 |
| EBIT 1 | 479.6 | 572.7 | 685.2 | 661.9 | 582.8 | 649 | 740.7 | 814.3 |
| Net income 1 | 325.5 | 409.6 | 510.2 | 496.5 | 456.3 | 489 | 561.7 | 628 |
| Net Debt 1 | -389.8 | -742.6 | -450.4 | -426.4 | -500.8 | -710.4 | -892.8 | -1,071 |
| Reference price 2 | 45.38 | 53.55 | 56.40 | 48.98 | 66.75 | 76.80 | 76.80 | 76.80 |
| Nbr of stocks (in thousands) | 99,256 | 99,191 | 98,904 | 99,210 | 97,556 | 97,999 | - | - |
| Announcement Date | 08/03/22 | 08/03/23 | 29/02/24 | 06/03/25 | 05/03/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 35.6x | 6.11x | 22.73x | 0.76% | 122B | ||
| 40.78x | 6.97x | 26.1x | 1.5% | 40.56B | ||
| 33.75x | 4.34x | 16.01x | 0.1% | 31.84B | ||
| 25x | 3.65x | 15.7x | 0.94% | 30.43B | ||
| 20.94x | 1.73x | 12.76x | 2.32% | 29.68B | ||
| 28.33x | 4.67x | 16.72x | 1.41% | 27.98B | ||
| 25.56x | 3.06x | 13.35x | 1.48% | 27.68B | ||
| 26.09x | 3.36x | 16.02x | 1.75% | 23.79B | ||
| Average | 29.51x | 4.24x | 17.42x | 1.28% | 41.77B | |
| Weighted average by Cap. | 31.67x | 4.86x | 19.22x | 1.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ANDR Stock
- ANDR Stock
- Valuation Andritz
Select your edition
All financial news and data tailored to specific country editions
















